10-Q: Nanophase Technologies Reports Q1 2024 Results, Driven by Solsence Growth

Nanophase Technologies saw increased revenue in Q1 2024, primarily driven by growth in its Solsence product line, despite a decrease in medical diagnostics sales.

Summary

• Nanophase Technologies Corporation reported its financial results for the first quarter of 2024, showing a net income of $893,000, a significant improvement compared to a net loss of $1,159,000 in the same period last year.
• Total revenue increased to $9.868 million, up from $9.457 million in Q1 2023, with product revenue reaching $9.772 million.
• The company's Solsence product line experienced substantial growth, contributing 35% of total revenue from one customer alone, while sales of personal care ingredients decreased.
• Cost of revenue decreased to $6.288 million, down from $7.308 million in Q1 2023, due to operational efficiencies in Solsence manufacturing.
• Research and development expenses decreased to $910,000, and selling, general, and administrative expenses decreased to $1.559 million, primarily due to lower legal costs.
• The company issued 15,000 shares of Series X Preferred Stock for $6 million, which is convertible into common stock and has a liquidation preference of $400 per share.
• The company's loan agreements with Strandler, LLC and Beachcorp, LLC are set to expire on October 1, 2025.
• The company has federal net operating loss carryforwards of approximately $50 million and Illinois net loss deduction carryforwards of approximately $21.3 million.

Sentiment

Score: 7

Explanation: The document shows a positive turnaround in profitability and revenue growth, particularly in the Solsence product line. However, there are still risks related to customer concentration, supply agreements, and potential capital needs. The settlement with BASF is a positive development, but the company needs to manage its supply agreements carefully. Overall, the sentiment is cautiously optimistic.

Positives

• The company achieved a net profit of $893,000 in Q1 2024, a significant improvement from the net loss in the same period last year.
• Revenue increased year-over-year, driven by strong growth in the Solsence product line.
• Cost of revenue decreased due to improved operational efficiencies.
• The company successfully settled a legal dispute with BASF, which included amendments to their supply agreement.
• The company secured $6 million in funding through the issuance of Series X Preferred Stock.

Negatives

• Sales of personal care ingredients and medical diagnostics materials decreased compared to the same period last year.
• The company's largest customer in personal care ingredients saw a decrease in sales.
• The company experienced a decrease in other revenue, which is typically comprised of developmental or licensing fees.
• The company's loan agreements with Strandler, LLC and Beachcorp, LLC are set to expire on October 1, 2025, which may require refinancing or other capital raising activities.

Risks

• The company is dependent on a limited number of key customers, and a cancellation of a purchase order or supply agreement could significantly impact revenue.
• The company's supply agreement with BASF could trigger a requirement to sell equipment to that customer.
• The company may face challenges in obtaining working capital on acceptable terms or at all.
• The company's ability to pass through material cost increases to customers is not guaranteed.
• The company faces uncertain demand for its Solsence products and advanced materials.
• The company has limited marketing experience, particularly with its Solsence product line.
• The company is dependent on patents and protection of proprietary information.
• The company may be impacted by new governmental regulations, especially those related to nanomaterials.
• The company could experience business interruptions due to unexpected events or public health crises.
• The company's future utilization of net operating loss carryforwards may be subject to certain limitations.

Future Outlook

The company expects capital spending for 2024 to be between $3 million and $6 million, funded by profit from operations, existing loans, and possible new debt financing. The company anticipates continued growth in its Solsence product line and will focus on reducing controllable variable product manufacturing costs. The company also expects that as product revenue volume increases, fixed manufacturing costs will be more efficiently absorbed, leading to increased margins.

Management Comments

• Management believes that the growth in the beauty science market is happening now due to a confluence of our technology, market conditions that favor what we produce, and our expanded expertise in these areas.
• Management plans on expanding efforts in areas where they have proven they can deliver innovation and growth.
• Management expects that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow.

Industry Context

The company's focus on skin health and beauty science aligns with growing consumer demand for clean and inclusive beauty products. The company's vertical integration and proprietary technology platform provide a competitive advantage in this market. The decrease in demand for medical diagnostics ingredients reflects a broader trend of reduced COVID-19 testing.

Comparison to Industry Standards

• Nanophase's revenue growth is notable compared to some smaller materials science companies, but it is still relatively small compared to larger players in the personal care ingredients market like Evonik or Croda.
• The company's gross margin improvement is a positive sign, but it needs to be sustained and improved further to reach industry benchmarks set by companies like Ashland or Sensient Technologies.
• The company's investment in Solsence is a strategic move to capture higher-margin finished product sales, similar to how some ingredient suppliers have expanded into branded products.
• The settlement with BASF is a positive development, but the company needs to manage its supply agreements carefully to avoid future disputes, similar to how other companies in the chemical industry manage their contracts.
• The company's reliance on related-party debt is not uncommon for smaller companies, but it is important to diversify funding sources as the company grows, similar to how other companies have transitioned to bank loans or public debt.

Legal Proceedings

• The company settled a legal dispute with BASF, which included amendments to their supply agreement and a new product development agreement.

Related Party Transactions

• The company has loan agreements with Beachcorp, LLC and Strandler, LLC, which are affiliates of a major shareholder and a director.
• The company issued 15,000 shares of Series X Preferred Stock to Strandler, LLC.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and the potential for future growth.
• Employees may benefit from the company's growth and expansion.
• Customers will benefit from the company's innovative products and technologies.
• Suppliers may benefit from the company's increased production and sales.
• Creditors may be impacted by the company's debt obligations and potential capital needs.

Next Steps

• The company will focus on expanding its Solsence product line and reducing manufacturing costs.
• The company will continue to develop new product formulations and technologies.
• The company will work to expand its customer base and explore new markets.
• The company will need to address its upcoming loan maturities with Strandler, LLC and Beachcorp, LLC.
• The company will need to manage its supply agreements carefully to avoid future disputes.

Key Dates

Keywords

Solsence, Nanophase Technologies, skin health, personal care ingredients, advanced materials, zinc oxide, financial results, preferred stock, BASF, legal settlement